Journal
NATURE REVIEWS DRUG DISCOVERY
Volume 15, Issue 11, Pages 751-769Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/nrd.2016.175
Keywords
-
Funding
- program Paris Alliance of Cancer Research Institutes (PACRI), Investissements d'Avenir [ANR-11-PHUC-002]
- 7th Framework Programme of the European Commission (LEISHDRUG project) [223414]
- French Government [ANR-10-LABX-62-IBEID]
- France BioImaging (FBI) [ANR-10-INSB-04-01]
- Fondation Francaise pour la Recherche Medicale (FRM)
- Research Councils UK (RCUK)
- Hungarian National Brain Research Program (grant MTA-SE-NAPB-BIOMAG)
- TEKES Finland Distinguished Professor Programme (FiDiPro) Fellow Grant [40294/13]
- Spanish Ministry of Economy and Competitiveness (MINECO)
- Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC) foundation
- Severo Ochoa Center of Excellence (MINECO award) [SEV-2015-0505]
- MINECO [BIO2014-62200-EXP]
- Innovative Training Networks (ITN) EU Horizon (EU-H) programme [641639 BIOPOL]
- European Union [258068]
- EU-FP7 Systems Microscopy Network of Excellence (NoE) project
- Sigrid Juselius Foundation
- Cancer Society of Finland
- Academy of Finland (Centre of Excellence in Translational Cancer Biology)
- Magnus Ehrnrooth foundation
- TEKES FiDiPro Fellow Grant [40294/13]
- TEKES New Generation Biobanking Grant [40294/11]
- K. Wallenberg and A. Wallenberg [2015.0291]
- Karolinska Institutet
- Ecole Polytechnique Federale de Lausanne (EPFL)
- Swiss National Science Foundation/National Centres of Competence in Research (SNF/NCCR) in Chemical Biology
- Cancer Research UK (CRUK)
- Higher Education Funding Council for England (HEFCE)
Ask authors/readers for more resources
The common and persistent failures to translate promising preclinical drug candidates into clinical success highlight the limited effectiveness of disease models currently used in drug discovery. An apparent reluctance to explore and adopt alternative cell-and tissue-based model systems, coupled with a detachment from clinical practice during assay validation, contributes to ineffective translational research. To help address these issues and stimulate debate, here we propose a set of principles to facilitate the definition and development of disease-relevant assays, and we discuss new opportunities for exploiting the latest advances in cell-based assay technologies in drug discovery, including induced pluripotent stem cells, three-dimensional (3D) co-culture and organ-on-a-chip systems, complemented by advances in single-cell imaging and gene editing technologies. Funding to support precompetitive, multidisciplinary collaborations to develop novel preclinical models and cell-based screening technologies could have a key role in improving their clinical relevance, and ultimately increase clinical success rates.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available